0000902664-23-004754.txt : 20230914
0000902664-23-004754.hdr.sgml : 20230914
20230914125311
ACCESSION NUMBER: 0000902664-23-004754
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230912
FILED AS OF DATE: 20230914
DATE AS OF CHANGE: 20230914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Avoro Capital Advisors LLC
CENTRAL INDEX KEY: 0001633313
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 231254580
BUSINESS ADDRESS:
STREET 1: 110 GREENE STREET
STREET 2: SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
BUSINESS PHONE: 212-937-4975
MAIL ADDRESS:
STREET 1: 110 GREENE STREET
STREET 2: SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
FORMER NAME:
FORMER CONFORMED NAME: venBio Select Advisor LLC
DATE OF NAME CHANGE: 20150210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aghazadeh Behzad
CENTRAL INDEX KEY: 0001701815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 231254579
MAIL ADDRESS:
STREET 1: C/O AVORO CAPITAL ADVISORS LLC
STREET 2: 110 GREENE STREET, SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4
1
ownership.xml
X0508
4
2023-09-12
1
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001633313
Avoro Capital Advisors LLC
110 GREENE STREET
SUITE 800
NEW YORK
NY
10012
0
0
1
0
0001701815
Aghazadeh Behzad
C/O AVORO CAPITAL ADVISORS LLC
110 GREENE STREET, SUITE 800
NEW YORK
NY
10012
0
0
1
0
0
Put Option (obligation to buy)
17.00
2023-09-12
4
S
0
1500
1
D
2023-09-12
2023-10-20
Common Stock
150000
1500
I
See footnotes
Put Option (obligation to buy)
17.00
2023-09-12
4
S
0
300
0.998
D
2023-09-12
2023-10-20
Common Stock
30000
300
I
See footnotes
Put Option (obligation to buy)
17.00
2023-09-13
4
S
0
250
0.9848
D
2023-09-13
2023-10-20
Common Stock
25000
250
I
See footnotes
Put Option (obligation to buy)
17.00
2023-09-13
4
S
0
950
1.0963
D
2023-09-13
2023-10-20
Common Stock
95000
950
I
See footnotes
Pre-funded Warrant (right to buy)
0.0001
2023-09-12
4
P
0
583771
17.1299
A
Common Stock
583771
583771
I
See footnotes
The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after September 14, 2023, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein and all other warrants beneficially owned by the Reporting Persons contain an exercise limitation prohibiting the holder from exercising the Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, none of the warrants beneficially owned by the Reporting Persons are presently exercisable.
Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer
2023-09-14
/s/ Behzad Aghazadeh
2023-09-14